Clinical Research Focus. 36th Edition
Reflections on ASH 2024: Transformative Breakthroughs in Hematology-Oncology
The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10 in San Diego and online, delivered on its promise of showcasing groundbreaking advancements in hematology and oncology. Cromos Pharma’s CEO Vlad Bogin attended this event and prepared his takeaways on the most exciting and impactful insights shared at the conference.
Please follow the link to learn more.
FDA Approves Crenessity: A Breakthrough Treatment for Congenital Adrenal Hyperplasia
The FDA has approved Crenessity (crinecerfont) for adults and children aged 4+ with classic congenital adrenal hyperplasia (CAH). Used alongside glucocorticoids, Crenessity helps control androgen levels and reduces steroid dosage, providing a significant advancement for CAH patients.
Please follow the link to learn more.
2024’s Top 12 Clinical Trials: Transforming the Future of Medicine
As 2024 draws to a close, it’s time to reflect on a year that has redefined the landscape of clinical research, driving scientific breakthroughs and transforming patient outcomes worldwide. This year’s trials have delivered hope across fields like oncology, metabolic health, and rare diseases, highlighting the biopharma industry’s dedication to addressing unmet medical needs and advancing future therapies. This article highlights 12 impactful clinical trials of 2024 that are reshaping healthcare and driving progress in this transformative era.
Please follow the link to learn more.
EMA Recommends First Oral Treatment for von Hippel-Lindau, a Rare Genetic Disorder
The European Medicines Agency has recommended Welireg (belzutifan) for conditional approval to treat adults with von Hippel-Lindau (VHL) disease-associated tumors and advanced clear cell renal cell carcinoma (RCC). Welireg offers new hope for patients with limited treatment options by targeting tumour growth caused by defective VHL protein.
Please follow the link to learn more.
Exploring Türkiye’s Edge in Clinical Research: Insights into Hospital Systems and Regulatory Framework
Türkiye is emerging as a global hub for clinical trials, thanks to its advanced healthcare infrastructure, diverse hospital systems, and alignment with international standards. In an exclusive interview, Seniz Sagol, Türkiye Country Head at Cromos Pharma, highlights the nation’s unique advantages, including streamlined regulatory processes and exceptional site capacity.
Please follow the link to learn more.
Lilly’s Zepbound Delivers 47% Greater Weight Loss Than Wegovy in Head-to-Head Trial
Eli Lilly’s SURMOUNT-5 trial revealed that Zepbound® (tirzepatide) achieved an average weight loss of 20.2%, compared to 13.7% with Wegovy®. As the only FDA-approved dual GIP and GLP-1 receptor agonist, Zepbound is redefining obesity treatment outcomes.
Please follow the link to learn more.
Prenatal Blood Tests Reveal Hidden Maternal Cancers in Nearly Half of Abnormal Cases
A groundbreaking NIH study has discovered that nearly 48.6% of pregnant individuals with abnormal prenatal cfDNA test results had previously undetected cancers, including colorectal, breast, lung, and pancreatic cancers. The findings highlight the potential of cfDNA testing to not only screen for fetal chromosomal disorders but also serve as an early cancer detection tool for asymptomatic pregnant individuals. Whole-body MRI proved the most effective follow-up method for confirming cancer diagnoses.
Please follow the link to learn more.
Nivolumab Improves Survival in Advanced Hodgkin’s Lymphoma: New Phase 3
A pivotal phase 3 trial shows that Nivolumab + AVD significantly improves progression-free survival compared to Brentuximab Vedotin + AVD in patients with advanced-stage Hodgkin’s lymphoma. The study highlights better outcomes and fewer side effects with nivolumab, marking a potential new standard of care.
Please follow the link to learn more.
